These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 1638080)

  • 21. [Study of the clinical pharmacokinetics of fotemustine in various tumor indications].
    Lokiec F; Beerblock K; Deloffre P; Lucas C; Bizzari JP
    Bull Cancer; 1989; 76(10):1063-9. PubMed ID: 2635634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II multicentre study of the nitrosourea fotemustine in inoperable squamous cell lung carcinoma.
    Le Chevalier T; Zabbe C; Gouva S; Cerrina ML; Quoix E; Riviere A; Berthaud P; Prache C; Berille J
    Eur J Cancer Clin Oncol; 1989 Nov; 25(11):1651-2. PubMed ID: 2687005
    [No Abstract]   [Full Text] [Related]  

  • 23. Fotemustine in the treatment of brain primary tumors and metastases.
    Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
    Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Focus on Fotemustine.
    De Rossi A; Rossi L; Laudisi A; Sini V; Toppo L; Marchesi F; Tortorelli G; Leti M; Turriziani M; Aquino A; Bonmassar E; De Vecchis L; Torino F
    J Exp Clin Cancer Res; 2006 Dec; 25(4):461-8. PubMed ID: 17310834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medical treatment and other combination regimens.
    Bajetta E; Del Vecchio M; Bajetta R; Canova S
    Tumori; 2007; 93(3):suppl 22-6. PubMed ID: 17679485
    [No Abstract]   [Full Text] [Related]  

  • 26. Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients.
    Voelter V; Schalenbourg A; Pampallona S; Peters S; Halkic N; Denys A; Goitein G; Zografos L; Leyvraz S
    Melanoma Res; 2008 Jun; 18(3):220-4. PubMed ID: 18477897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe neurological disabilities after complete remission of advanced malignant melanoma following fotemustine therapy in combination with total brain irradiation.
    Gruss C; Geissler A; Schalke B; Landthaler M; Stolz W
    Melanoma Res; 2002 Aug; 12(4):403-4. PubMed ID: 12170192
    [No Abstract]   [Full Text] [Related]  

  • 28. Permeability of two nitrosoureas, carmustine and fotemustine in rat cortex.
    Meulemans A; Giroux B; Hannoun P; Henzel D; Bizzari JP; Mohler J
    Chemotherapy; 1989; 35(5):313-9. PubMed ID: 2791708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interim report of phase II study of new nitrosourea S 10036 in disseminated malignant melanoma.
    Khayat D; Bizzari JP; Frenay M; Naman H; Weil M; Goupil A; Namer M; Rouesse J; Banzet P; Jacquillat C
    J Natl Cancer Inst; 1988 Nov; 80(17):1407-8. PubMed ID: 3172267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I pharmacological study of intra-arterially infused fotemustine for colorectal liver metastases.
    Hartmann JT; Schmoll E; Bokemeyer C; Fety R; Lucas C; Giroux B; Schmoll HJ
    Eur J Cancer; 1998 Jan; 34(1):87-91. PubMed ID: 9624243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional and morphological effects of fotemustine on the auditory system of the rat.
    Gocer C; Eryilmaz A; Kayikci ME; Korkmaz H; Surucu S; Akmansu SH
    J Laryngol Otol; 2008 Jun; 122(6):551-6. PubMed ID: 17888195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and pharmacodynamics of nitrosourea fotemustine: a French cancer centre multicentric study.
    Iliadis A; Launay-Iliadis MC; Lucas C; Fety R; Lokiec F; Tranchand B; Milano G
    Eur J Cancer; 1996 Mar; 32A(3):455-60. PubMed ID: 8814692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Logistic regression model of fotemustine toxicity combining independent phase II studies.
    Raymond E; Haon C; Boaziz C; Coste M
    Cancer; 1996 Nov; 78(9):1980-7. PubMed ID: 8909320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy.
    Leyvraz S; Spataro V; Bauer J; Pampallona S; Salmon R; Dorval T; Meuli R; Gillet M; Lejeune F; Zografos L
    J Clin Oncol; 1997 Jul; 15(7):2589-95. PubMed ID: 9215829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemical and glutathione conjugation-related degradation of fotemustine: formation and characterization of a glutathione conjugate of diethyl (1-isocyanatoethyl)phosphonate, a reactive metabolite of fotemustine.
    Brakenhoff JP; Commandeur JN; de Kanter FJ; van Baar BL; Luijten WC; Vermeulen NP
    Chem Res Toxicol; 1994; 7(3):380-9. PubMed ID: 8075370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The mechanism of action of the nitrosourea anti-tumor drugs on thioredoxin reductase, glutathione reductase and ribonucleotide reductase.
    Schallreuter KU; Gleason FK; Wood JM
    Biochim Biophys Acta; 1990 Aug; 1054(1):14-20. PubMed ID: 2200526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II and pharmacokinetic study of fotemustine in inoperable colorectal cancer.
    Rougier P; Chabot GG; Bonneterre J; Tigaud JM; Lucas C; Baud M; Bérille J; Gouyette A
    Eur J Cancer; 1993; 29A(2):288-9. PubMed ID: 8422301
    [No Abstract]   [Full Text] [Related]  

  • 38. Fotemustine in patients with advanced gastric cancer, a phase II trial from the EORTC-GITCCG (European Organization for Research and Treatment of Cancer, Gastrointestinal Tract Cancer Cooperative Group).
    Rougier P; van Pottelsberghe C; Kok T; Paillot B; Wagener T; De Greve J; Fabri MC; Gerard B; Van Glabbeke M; Bleiberg H
    Eur J Cancer; 1996 Jul; 32A(8):1432-3. PubMed ID: 8869111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
    Del Vecchio M; Mortarini R; Canova S; Di Guardo L; Pimpinelli N; Sertoli MR; Bedognetti D; Queirolo P; Morosini P; Perrone T; Bajetta E; Anichini A
    Clin Cancer Res; 2010 Dec; 16(23):5862-72. PubMed ID: 21030496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal effects of S10036 in man.
    Deray G; Khayat D; Jacquiaud C; Bizzari JP; Bourbouze R; Musset L; Jaudon MC; Baumelou B; Jacquillat C; Jacobs C
    Cancer Chemother Pharmacol; 1990; 26(6):467-8. PubMed ID: 2225319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.